• 1
    Global Malaria Action Plan. The Roll Back Malaria Partnership. Geneva: World Health Organization, 2008; Available at (last accessed November 2010).
  • 2
    World Malaria Report 2010. Geneva: World Health Organization, 2010; (ISBN 978 92 4 156410 6).
  • 3
    World Malaria Report 2008. Geneva: World Health Organization, 2008; (ISBN 978 92 4 156369 7).
  • 4
    Karunaweera ND, Wijesekera SK, Wanasekera D, Mendis KN, Carter R. The paroxysm of Plasmodium vivax malaria. Trends Parasitol 2003; 19: 188193.
  • 5
    Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect Dis 2005; 18: 531536.
  • 6
    Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report. Southeast Asian J Trop Med Public Health 1991; 22: 380385.
  • 7
    Meshnick SR, Taylor TE, Kamchonwongpaisan S. Arteminisin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60: 301315.
  • 8
    Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Tomas JS, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430: 900904.
  • 9
    Valecha N, Looareesuwan S, Martensson A, Abdulla SM, Krudsood S, Tangpukdee N, Mohanty S, Mishra SK, Tyagi PK, Sharma SK, Moehrle J, Gautam A, Roy A, Paliwal YK, Kothari M, Saha N, Dash AP. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 2010; 51: 684691.
  • 10
    Ollario P, Wells TNC. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 2009; 85: 584595.
  • 11
    Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FCK, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 2011; 108: 44004405.
  • 12
    FDA Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 2005.
  • 13
    FDA Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies, 2002.
  • 14
    Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q, Keeratithakul D, Sirisopana N, Luesutthiviboon L, Brewer TG, Kyle DE. Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 2001; 65: 717721.
  • 15
    Snyder C, Chollet J, Santo-Tomas J, Scheurer C, Wittlin S. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol 2007; 115: 296300.
  • 16
    Teja-Isavadharm P, Peggins JO, Brewer TG, White NJ, Webster HK, Kyle DE. Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Antimicrob Agents Chemother 2004; 48: 954960.
  • 17
    Davis TME, England M, Dunlop A-M, Page-Sharp M, Cambon N, Keller TG, Heidecker JL, Ilett KF. Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers. Antimicrob Agents Chemother 2007; 51: 10991101.
  • 18
    Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 2008; 64: 683690.
  • 19
    Binh TQ, Ilett KE, Batty KT, Davis TME, Hung NC, Powell SM, Thu LTA, Thien HV, Phuöng HL, Phuong VDB. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol 2001; 51: 541546.
  • 20
    Kongpatanakul S, Chatsiricharoenkul S, Sathirakul K, Suputtamongkol Y, Atipas S, Watnasirichaikul S, Pongnarin P, Sangvanich P. Evaluation of the safety and relative bioavailability of a new dihydroartemisinin tablet formulation in healthy Thai volunteers. Trans R Soc Trop Med Hyg 2007; 101: 972979.
  • 21
    Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 2004; 98: 261267; discussion 268–9.